The objective of the study was to explore the possible formation of the inclusion complex of lacidipine (LCDP), a class II drug under biopharmaceutics classification system (BCS) with beta-cyclodextrin (β-CD) and modified β-CDs: hydroxy propyl- beta-cyclodextrin (HP-β-CD) and sulfobutyl ether-beta-cyclodextrin (SBE-β-CD) in order to enhance the solubility and the dissolution rate of the drug with an intention to improve its bioavailability. The stability constants found using phase solubility studies showed that SBE-β-CD formed the most stable inclusion complex with the drug (K = 348 ± 4 M-1) compared to the other cyclodextrins (CDs). The thermal analysis confirmed this finding. IR spectral analysis indicated the involvement of the hydroxyl function of CDs with the COOH of the drug. H1 NMR and 13C NMR spectral analysis indicated that the aromatic ring of drug included deeply in the CD cavity leaving the side chain protruding outside the CD cage and hydrogen bonds are formed which stabilizes the complex formation. The dissolution of the drug was improved on complexation with SBE-β-CD more effectively compared to the other CDs. The in vivo pharmacokinetic study of the complexes in Wistar rats showed an increase in AUC value by 1.5-2 times in case of (HP-β-CD) and SBE-β-CD compared to the plain drug and maximum with SBE-β-CD complex (Cmax = 242 ± 150 ng/ml, AUC = 1506.95 ± 0.505 ng/ml h).
|Number of pages||11|
|Journal||Journal of Inclusion Phenomena and Macrocyclic Chemistry|
|Publication status||Published - 01-04-2016|
All Science Journal Classification (ASJC) codes
- Food Science
- Condensed Matter Physics